| Reduced Risk Status: |
|
| IPM Compatibility: |
PER REQUESTOR, VERYGOODFIT; RESISTANCE MANAGEMENT. NEW FRAC GROUP FOR THIS USE. VERYGOODFIT; NO IMPACT ON BENEFICIALS. REDUCED RISK- USEPA.
|
| Reasons for need: |
BOTRYTIS, FUSARIUM, ALTERNARIA, PM; RESISTANCE MANAGEMENT. NEW FRAC GROUP FOR THIS USE.
|
| Requesting State(s): |
CA:Sfetcu, D ; FL:Bledsoe, M* ;
|
| PCR Use Pattern: |
KINOPROL, 0.03 TO 0.065 LB AI/A, FOLIAR AND DRIP, 3 APPLICATIONS WITH 7 DAY RETREATMENT INTERVAL AND 0 DAY PHI.
|
| EPA Default Residue Trials: |
ANY 4 TRIALS
|
| IR-4 Residue Trial Plan: |
ANY 4 TRIALS
|
| Residue Protocol Use Pattern: |
|
| Efficacy/Crop Safety (E/CS) Data Required: |
|
| E/CS Research Comments: |
|
| Label Use Pattern Submitted To EPA: |
|
| EPA PIF Status: |
EPA GREEN 08/22; Red:09/23
|
| EPA Status: |
|
| EPA PRIA Date: |
|
| MRID: |
|
| Comments: |
AS CONFIRMED BY KRITEN KNOX:07/22; EPA GREEN 08/22; MFG requires NDA prior to trial initiation 5/23, JPB; Changed from MFG WILL NOT SUPPORT to POTENTIAL: E/CS DATA BEFORE APPROVAL FOR RESIDUE, 07/23, JPB; Advised EPA Hold at 2023 FUW:09/23/sb
|
| International Status: |
|
| Archive Location: |
|
| QA Archive: |
|